ClinicalTrials.gg
CompletedNCT00141362Updated Jan 1, 2007

Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.

A Phase 3 interventional study of Pregabalin in Pain, sponsored by Pfizer. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-01-01.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.

Enrollment
11th of 55
325 · median 64
Started
2001
the only one that year
Phase 3
15 of 55
none open now
Registered
1st of 55
by date
Lead sponsor
2 of 55
Pfizer

Among the 55 studies testing pregabalin in Pain, this one is the 11th largest by enrollment, is the only one that started in 2001, is one of 15 in phase 3, and was the 1st registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing pregabalin in Pain, or all of them as a file.
02

Study summary

Evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have met the inclusion criteria for the preceding double-blind BID study in diabetic neuropathy or postherpetic neuralgia.
  • Must have received study medication under double-blind conditions.

Exclusion criteria

Exclusion Criteria:

  • Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
325 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and efficacy

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2001 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Oct 2001
Completion
Aug 2005
Last update
Jan 1, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 1, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00141362
Lead sponsor
Pfizer
First posted
Sep 1, 2005
Start date
Oct 2001
Completion
Aug 2005
Last update
Jan 1, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion